Literature DB >> 7573455

High-affinity CCK receptors are coupled to phospholipase A2 pathways to mediate pancreatic amylase secretion.

Y Tsunoda1, C Owyang.   

Abstract

It is well recognized that JMV-180, a cholecystokinin (CCK) analogue, acts as an agonist on the high-affinity CCK receptor in pancreatic acinar cells. It caused Ca2+ oscillations and amylase secretion in a manner independent of the phospholipase C-inositol 1,4,5-trisphosphate (IP3) pathway. We investigated the mechanism by which the high-affinity CCK receptor utilizes IP3-independent Ca2+ signal transduction to mediate amylase secretion. JMV-180 (1-1,000 nM)-stimulated Ca2+ oscillations and amylase secretion were significantly inhibited by the phospholipase A2 (PLA2) inhibitor, ONO-RS-082 (10 microM). Using streptolysin O-permeabilized cells, we showed that a porcine pancreatic anti-PLA2 antibody from rabbit serum (250 ng/ml) inhibited JMV-180-stimulated amylase secretion. In contrast to CCK octapeptide, JMV-180 (1 nM-10 microM) had no effect on intracellular IP3 levels. These concentrations of JMV-180 did, however, increase intracellular levels of arachidonic acid (AA) metabolite by 2.5-fold in a biphasic manner. Application of exogenous AA (10 microM) released 60% of ATP-incorporated 45Ca2+ from permeabilized pancreatic acini within 3 min in a transient manner. We also showed that active phorbol ester (100 nM) inhibited Ca2+ oscillations and amylase secretion stimulated by JMV-180 (10 nM) or CCK-OPE (100 nM). Application of Mn2+ (2 mM) to superfused acini resulted in a rapid quench of fura 2 fluorescence during 10 nM JMV-180 stimulation, suggesting an involvement of extracellular Ca2+ influx. However, the major source of Ca2+ utilized for oscillations during high-affinity CCK receptor activation was intracellular. In conclusion, we have demonstrated that the high-affinity CCK receptors are coupled to PLA2 pathways to produce AA, which mediates cytosolic Ca2+ oscillation and monophasic amylase secretion, in rat pancreatic acinar cells.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7573455     DOI: 10.1152/ajpgi.1995.269.3.G435

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  9 in total

1.  Contributing mechanisms underlying desensitization of cholecystokinin-induced activation of primary nodose ganglia neurons.

Authors:  Cody W Kowalski; Jonathan E M Lindberg; Daniel K Fowler; Steven M Simasko; James H Peters
Journal:  Am J Physiol Cell Physiol       Date:  2020-02-19       Impact factor: 4.249

2.  Synthetic peptides containing a BXBXXXB(B) motif activate phospholipase C-beta1.

Authors:  A Piiper; D Stryjek-Kaminska; D Illenberger; R Klengel; J M Schmidt; P Gierschik; S Zeuzem
Journal:  Biochem J       Date:  1997-09-15       Impact factor: 3.857

3.  Bicarbonate and fluid secretion evoked by cholecystokinin, bombesin and acetylcholine in isolated guinea-pig pancreatic ducts.

Authors:  G Szalmay; G Varga; F Kajiyama; X S Yang; T F Lang; R M Case; M C Steward
Journal:  J Physiol       Date:  2001-09-15       Impact factor: 5.182

4.  Pharmacological investigations of the cellular transduction pathways used by cholecystokinin to activate nodose neurons.

Authors:  Huan Zhao; Dallas C Kinch; Steven M Simasko
Journal:  Auton Neurosci       Date:  2011-06-12       Impact factor: 3.145

5.  Agonist activation of arachidonate-regulated Ca2+-selective (ARC) channels in murine parotid and pancreatic acinar cells.

Authors:  Olivier Mignen; Jill L Thompson; David I Yule; Trevor J Shuttleworth
Journal:  J Physiol       Date:  2005-03-10       Impact factor: 5.182

Review 6.  Involvement of endogenous CCK and CCK1 receptors in colonic motor function.

Authors:  Gábor Varga; András Bálint; Beáta Burghardt; Massimo D'Amato
Journal:  Br J Pharmacol       Date:  2004-04       Impact factor: 8.739

Review 7.  Therapeutic potential for novel drugs targeting the type 1 cholecystokinin receptor.

Authors:  Erin E Cawston; Laurence J Miller
Journal:  Br J Pharmacol       Date:  2009-11-18       Impact factor: 8.739

8.  Serotonin and cholecystokinin synergistically stimulate rat vagal primary afferent neurones.

Authors:  Y Li; X Y Wu; C Owyang
Journal:  J Physiol       Date:  2004-07-02       Impact factor: 5.182

9.  Comparative pharmacology of cholecystokinin induced activation of cultured vagal afferent neurons from rats and mice.

Authors:  Dallas C Kinch; James H Peters; Steven M Simasko
Journal:  PLoS One       Date:  2012-04-13       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.